Pedro Rosa-Neto

Jun 3, 2024 | nature.com | Giulia Baracchini |Pedro Rosa-Neto |Judes Poirier |Sylvia Villeneuve |Taylor W. Schmitz |Gary Turner | +2 more

AbstractThe neuromodulatory subcortical nuclei within the isodendritic core (IdC) are the earliest sites of tauopathy in Alzheimer’s disease (AD). They project broadly throughout the brain’s white matter. We investigated the relationship between IdC microstructure and whole-brain white matter microstructure to better understand early neuropathological changes in AD.

May 3, 2024 | nature.com | Gleb Bezgin |Thomas K. Karikari |Henrik Zetterberg |Kaj Blennow |Pedro Rosa-Neto

AbstractNeuronal dysfunction and cognitive deterioration in Alzheimer’s disease (AD) are likely caused by multiple pathophysiological factors. However, mechanistic evidence in humans remains scarce, requiring improved non-invasive techniques and integrative models.

Mar 13, 2024 | nature.com | Wagner S. Brum |Joseph Therriault |Eduardo Zimmer |Sebastian Palmqvist |Henrik Zetterberg |Kaj Blennow | +1 more

AbstractBlood-based biomarkers for screening may guide tau positrion emissition tomography (PET) scan referrals to optimize prognostic evaluation in Alzheimer’s disease. Plasma Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP were measured along with tau-PET in memory clinic patients with subjective cognitive decline, mild cognitive impairment or dementia, in the Swedish BioFINDER-2 study (n = 548) and in the TRIAD study (n = 179).

Sep 25, 2023 | nature.com | Bruna Bellaver |Guilherme Povala |Joseph Therriault |Cecile Tissot |Carolina Soares |Yi-ting Wang | +6 more

AbstractThe mechanisms by which the apolipoprotein E ε4 (APOEε4) allele influences the pathophysiological progression of Alzheimer’s disease (AD) are poorly understood. Here we tested the association of APOEε4 carriership and amyloid-β (Aβ) burden with longitudinal tau pathology.

Aug 31, 2023 | nature.com | Wagner S. Brum |Eduardo Zimmer |Joseph Therriault |Cecile Tissot |Hartmuth C. Kolb |Sebastian Palmqvist | +2 more

AbstractCost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer’s disease (AD). Blood biomarkers can accurately detect AD pathology, but it is unclear whether their incorporation into a full diagnostic workflow can reduce the number of confirmatory cerebrospinal fluid (CSF) or positron emission tomography (PET) tests needed while accurately classifying patients.